Axsome Therapeutics (AXSM): Bellevue Group AG reduced its stake -40K shares
Bellevue Group AG reduced its stake in Axsome Therapeutics, per its Q2 2025 13F.
- 56K
- Shares reported · -40K vs prior quarter
- 0.13%
- Disclosed portfolio weight
- $5.87M
- Reported value
- Holdings as of
- Jun 30, 2025
- Filed
- Aug 14, 2025
What stands out in this filing
- 96,407 shares in Q1 2025, 56,253 now (−41.7% in share count).
- Reported at $5.87M, 0.13% of the portfolio value in this 13F filing.
- 8 other tracked managers reported the same kind of change for Q2 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jun 16, 2025InsiderOfficer sold ~$768K of AXSM shares in the open market
- Jun 17, 2025InsiderOfficer sold ~$752K of AXSM shares in the open market
- Jun 18, 2025InsiderOfficer sold ~$757K of AXSM shares in the open market
- Jun 20, 2025InsiderOfficer sold ~$769K of AXSM shares in the open market
- Jun 23, 2025InsiderOfficer sold ~$602K of AXSM shares in the open market
What came next
- Aug 22, 2025InsiderDirector sold ~$2M of AXSM shares in the open market
- Aug 26, 2025InsiderDirector sold ~$2.4M of AXSM shares in the open market
- Aug 27, 2025InsiderDirector sold ~$2.45M of AXSM shares in the open market
- Aug 28, 2025InsiderDirector sold ~$2.43M of AXSM shares in the open market
- Aug 29, 2025InsiderDirector sold ~$2.43M of AXSM shares in the open market
- Sep 2, 2025InsiderDirector sold ~$1.67M of AXSM shares in the open market
- Sep 5, 2025InsiderDirector sold ~$1.14M of AXSM shares in the open market
- Sep 8, 2025Insider · 1 personInsiders: 3 purchases (~$200K)
- Sep 12, 2025InsiderCEO sold ~$3.32M of AXSM shares in the open market
- Sep 15, 2025InsiderCEO sold ~$1.79M of AXSM shares in the open market
- Sep 16, 2025Insider · 2 peopleInsiders: 3 sales (~$7.5M)
- Sep 22, 2025InsiderOfficer sold ~$1.16M of AXSM shares in the open market
- Nov 3, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Axsome Therapeutics
For Axsome Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AXSM page.
How this filing works
Explore the data
Common questions
What does this filing report about Axsome Therapeutics (AXSM) stock?
Bellevue Group AG reduced its stake in Axsome Therapeutics, per its Q2 2025 13F. Now 56K shares, $5.87M reported value, 0.13% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Jun 30, 2025. Filed: Aug 14, 2025.
What stands out in this filing?
96,407 shares in Q1 2025, 56,253 now (−41.7% in share count). Reported at $5.87M, 0.13% of the portfolio value in this 13F filing. 8 other tracked managers reported the same kind of change for Q2 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Axsome Therapeutics recently?
For Axsome Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the AXSM page.
Does this mean AXSM stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Axsome Therapeutics
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its AXSM page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data